Dergiler / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 6

Effect of hyperparathyroidism on coagulation: a global assessment by modified rotation thromboelastogram (ROTEM)

Sayfa
2897–2902
Yayın Tarihi
2022-11-06
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Hemostatic changes, do not seem to have an effect on increased cardiovascular mortality.Key words: Hyperparathyroidism, coagulation, thromboelastogram, ROTEM

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: Hyperparathyroidism is an endocrine disorder characterized by hypercalcemia.
📊
Temel Bulgular & Veri:Materials and methods: Twenty-two patients with primary hyperparathyroidism (PHPT) and 20 healthy controls were involved.
💡
Sonuç & Katkı:Hemostatic changes, do not seem to have an effect on increased cardiovascular mortality.Key words: Hyperparathyroidism, coagulation, thromboelastogram, ROTEM
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: Hyperparathyroidism is an endocrine disorder characterized by hypercalcemia. Because of calcium’s effects on parathyroid glands, bone, intestines, and kidneys, it has an important place in homeostasis. The results of studies regarding hyperparathyroidism hemostasis are conflicting. Thromboelastography helps to evaluate all steps of hemostatic system. Our aim in this study was to investigate the possible role of hemostatic mechanisms in the development of thrombosis in hyperparathyroid patients with the modified rotation thromboelastogram (ROTEM). Materials and methods: Twenty-two patients with primary hyperparathyroidism (PHPT) and 20 healthy controls were involved. This study was conducted in Eskisehir Osmangazi University Faculty of Medicine, Endocrinology and Hematology clinics for 2 years. The complete blood count, fibrinogen, D-dimer levels, prothrombin time, activated prothrombin time, and ROTEM parameters [clot formation time (CFT), clotting time (CT), and maximum clot formation (MCF)] were determined by two activated tests, INTEM and EXTEM analyses. A thromboelastographic evaluation was performed in the preoperative and postoperative (3 months after surgery) periods. Results: In INTEM assay, the CT (p = 0.012) and CFT (p = 0.07) values were increased in preoperative PHPT patients compared with the control group. Although there was a decrease in the postoperative CT and CFT values, no statistical difference was found. Conclusion: The prolongation of the CT and CFT values were consistent with a hypocoagulable state in patients with PHPT. Hyperparathyroidism causes a hypocoagulable state that can be successfully assessed by ROTEM. Hemostatic changes, do not seem to have an effect on increased cardiovascular mortality.Key words: Hyperparathyroidism, coagulation, thromboelastogram, ROTEM

🔖

Bu Makaleye Atıf Yap

BADAK, B., AKAY, O. M., YORULMAZ, G., BİLGİN, M., ALAGÜNEY, E. S., KEBAPÇI, N., GÜNDÜZ, E., EFE, B., AKALIN, A., BUYRUK, B. A., KALKAN, A. T. (2022). Effect of hyperparathyroidism on coagulation: a global assessment by modified rotation thromboelastogram (ROTEM). Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 6, 2897–2902. https://ajindex.com/articles/609938

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Hedback G, Tisell LE, Bengtsson BA, Hedman I, Oden A. Premature death in patients operated on for PHPT. World Journal of Surgery 1990; 14: 829- 835. doi: 10.1007/BF01670531
  2. Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nature Reviews Endocrinology 2018; 14 (2): 115-125. doi: 10.1038/nrendo.2017.104
  3. Erem C, Kocak M, Hacihasanoglu A, Yılmaz M, Saglam F et al. Blood coagulation; fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-dimer levels. Experimental and Clinical Endocrinology & Diabetes 2008; 116: 619- 624. doi: 10.1055/s-2008-1065365
  4. Erem C, Kocak M, Nuhoglu I, Yılmaz M, Ucuncu O. Increased plasma activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism. European Journal of Endocrinology 2009; 160: 863-868. doi: 10.1530/EJE-09-0069
  5. Franchello A, Camandona M, Gasparri G. Acute hyperparathyroidism and vascular thrombosis: an unrecognized association. Journal of Endocrinological Investigation 2010; 33 (9): 683. doi: 10.1007/BF03346669
  6. Farahnak P, Lärfars G, Sten-Linder M, Nilsson IL. Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. Journal of Clinical Endocrinology and Metabolism 2011; 96 (7): 2112-2118. doi: 10.1210/jc.2011- 0238
  7. Anderson JL, Vanwoerkum R, Horne BD, Bair TL, May HT et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? American Heart Journal 2011; 162: 331-339. doi: 10.1016/j.ahj.2011.05.005
  8. Boas WWV, Oliveira CB, Maximo TA. Thromboelastographic profile of patients with hyperparathyroidism secondary to chronic kidney failure submitted to total parathyroidectomy. Case Series Open Journal of Anesthesiology 2013; 3: 363-366
  9. Koufakis T, Antonopoulou V, Grammatiki M, Karras SN, Ajjan R et al. The relationship between primary hyperparathyroidism and thrombotic events: report of three cases and a review of potential mechanisms. International Journal of HematologyOncology and Stem Cell Research 2018; 1: 12 (3): 175-180
  10. Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperparathyroidism. New England Journal of Medicine 2004; 350 (17): 1746–1751. doi: 10.1056/NEJMcp032200
  11. Walker GL, Williamson PM, Ravich RB, Roche J. Hypercalcaemia associated with cerebral vasospasm causing